Sean Cassidy
Director of Finance/CFO chez Arvinas Operations, Inc.
Fortune : 8 M $ au 31/03/2024
Profil
Actuellement, Sean A. Cassidy est directeur financier d'Arvinas, Inc. et d'Arvinas Operations, Inc. (une filiale d'Arvinas, Inc.) et trésorier de The Friends of Yale New Haven Children's Hospital. Dans le passé, M. Cassidy a occupé les postes de directeur financier et de vice-président de l'administration chez Renetx Bio, Inc, de directeur financier et de vice-président chez CuraGen Corp, de directeur et contrôleur chez Deloitte & Touche LLP et de directeur et contrôleur chez 454 Life Sciences Corp. Il a obtenu un MBA et un diplôme de premier cycle à l'Université du Connecticut.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARVINAS, INC.
0,27% | 23/02/2024 | 181 916 ( 0,27% ) | 8 M $ | 31/03/2024 |
Postes actifs de Sean Cassidy
| Sociétés | Poste | Début |
|---|---|---|
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Director of Finance/CFO | - |
| The Friends of Yale New Haven Children's Hospital | Treasurer | - |
Anciens postes connus de Sean Cassidy
| Sociétés | Poste | Fin |
|---|---|---|
| ARVINAS, INC. | Director of Finance/CFO | 29/02/2024 |
Renetx Bio, Inc.
 Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Director of Finance/CFO | 01/06/2013 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Director of Finance/CFO | 01/10/2009 |
454 Life Sciences Corp.
 454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Director/Board Member | 01/12/2008 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Director/Board Member | 01/05/2001 |
Formation de Sean Cassidy
| University of Connecticut | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARVINAS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Renetx Bio, Inc.
Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
454 Life Sciences Corp.
454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Health Services |
| The Friends of Yale New Haven Children's Hospital |
